Loading organizations...
Halia Therapeutics develops novel therapies addressing the root causes of inflammatory and neurological diseases. The company specializes in first-in-class inflammasome inhibitors, modulating this key innate immune system component. Their technical approach mitigates chronic inflammation, a factor in many debilitating conditions, by restoring fundamental biological mechanisms.
Dr. John “Keoni” Kauwe founded Halia Therapeutics in 2017, inspired by research into genetic resilience. He observed individuals with the high-risk APOE4 gene for Alzheimer's disease who remained asymptomatic. This pivotal insight into innate protective mechanisms guides the company’s focus on enhancing human resilience through therapeutic innovation.
Halia Therapeutics targets patients suffering from chronic inflammatory and neurological conditions. The company's vision shifts the paradigm from treating illness to enhancing human resilience. By focusing on fundamental biological pathways, Halia aims to deliver treatments preventing or significantly altering complex disease progression, improving long-term patient outcomes.
Halia Therapeutics has raised $30.0M across 1 funding round.
Halia Therapeutics has raised $30.0M in total across 1 funding round.
Halia Therapeutics has raised $30.0M in total across 1 funding round.
Halia Therapeutics's investors include Todd Pedersen, Fin Capital, M13, Oak HC/FT, Peterson Ventures, Trajectory Ventures.
Halia Therapeutics has raised $30.0M across 1 funding round. Most recently, it raised $30.0M Series C in January 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2024 | $30M Series C | Todd Pedersen | FIN Capital, M13, OAK HC/FT, Peterson Ventures, Trajectory Ventures | Announced |
Halia Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies to treat chronic inflammatory disorders and neurological diseases. Their core product pipeline targets the underlying causes of inflammation by modulating specific genetic pathways, aiming to improve patient outcomes across a range of conditions including Alzheimer’s disease, myelodysplastic syndromes, and other inflammatory illnesses. The company serves patients with unmet medical needs driven by aberrant immune responses and is advancing multiple drug candidates through clinical trials, demonstrating promising early-stage growth momentum[1][2][3].
Founded in 2017 and headquartered in Lehi, Utah, Halia Therapeutics originated from research led by Dr. John “Keoni” Kauwe, who discovered a protective mutation in the RAB10 gene that guards against the harmful effects of the APOE4 gene variant linked to Alzheimer’s disease. This breakthrough inspired the company’s mission to decode genetic resilience and translate it into novel treatments. Initially focused on Alzheimer’s, Halia expanded its scope as the protective mutation was found to mitigate inflammation, a root cause of many chronic diseases. This evolution shaped their scientific platform targeting the NLRP3 inflammasome pathway to regulate systemic inflammation[2].
Halia Therapeutics is positioned at the intersection of genomics, immunology, and precision medicine, riding the trend of leveraging human genetic insights to develop targeted therapies. The timing is critical as chronic inflammation is increasingly recognized as a common pathway in many diseases, creating a large unmet medical need. Advances in genetic research and drug discovery technologies enable Halia to translate protective gene mutations into novel therapeutics, influencing the broader biopharmaceutical ecosystem by pioneering treatments that could shift paradigms in managing inflammatory and neurodegenerative diseases[2].
Looking ahead, Halia Therapeutics is expected to continue expanding its clinical pipeline and deepen its understanding of inflammation-related pathways. Trends such as personalized medicine, increased focus on neuroinflammation, and the growing prevalence of chronic inflammatory diseases will shape its trajectory. As clinical data matures, Halia’s influence may grow, potentially establishing it as a leader in inflammation-targeted therapies with broad applications. Their foundational mission to harness genetic resilience offers a compelling narrative that could drive innovation and patient impact in the years to come[1][2][3].
